AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28895673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active IFC group (N=30)
Number of subjects: 65
Study 28895673 — intervention group
Group type: COMPARATOR
Intervention: Sham IFC group (N=30)
Number of subjects: 65
Study 28895673 — intervention group
Group type: COMPARATOR
Intervention: Comparison between active IFC and sham IFC groups
Number of subjects: 65
Study 26740684 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g LNS/d
Number of subjects: 748
Study 26740684 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g LNS/d
Number of subjects: 748
Study 26740684 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g LNS/d
Number of subjects: 748
Study 26740684 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS intervention groups (10 g, 20 g, 40 g)
Number of subjects: 748
Study 26740684 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 748
Study 26740684 — intervention group
Group type: COMPARATOR
Intervention: Non-LNS CFs
Number of subjects: 748
Study 24890138 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg
Number of subjects: 190
Study 24890138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 22709949 — intervention group
Group type: EXPERIMENTAL
Intervention: 23vPPS vaccine (Pneumovax(®))
Number of subjects: 340
Study 22709949 — intervention group
Group type: COMPARATOR
Intervention: inactivated influenza vaccine (Fluarix(®))
Number of subjects: 340
Study 20479459 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic sling
Number of subjects: 597
Study 20479459 — intervention group
Group type: COMPARATOR
Intervention: Transobturator sling
Number of subjects: 597
Study 17460616 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 26
Study 15866560 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat plus CBTgsh (120 mg three times a day)
Number of subjects: 50
Study 15866560 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus CBTgsh
Number of subjects: 50
Study 15866560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 50
Study 12570939 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide plus enoxaparin
Number of subjects: 261
Study 12570939 — intervention group
Group type: COMPARATOR
Intervention: eptifibatide plus unfractionated heparin
Number of subjects: 261
Study 10554416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg/day for 2 weeks before surgery)
Number of subjects: 34
Study 8908527 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol with 150 micrograms desogestrel
Number of subjects: 1633
Study 8908527 — intervention group
Group type: COMPARATOR
Intervention: 20 micrograms ethinylestradiol with 150 micrograms desogestrel
Number of subjects: 1633
Study 1858442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1800-2400 mg per day for 3 weeks
Number of subjects: 17
Study 1858442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 17
Study 30738380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 454
Study 30738380 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 454
Study 28052714 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal ibuprofen
Number of subjects: 72
Study 28052714 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 72
Study 25884223 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR (seven weekly 90 minute sessions) + TAU
Number of subjects: 100
Study 25884223 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 100
Study 24229598 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (live combined bifidobacterium and lactobacillus tablets)
Number of subjects: 150
Study 24229598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunoglobulin (anti‐rotavirus egg yolk immunoglobulin, IgY)
Number of subjects: 150
Study 24229598 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 150
Study 21175873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 21
Study 21175873 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 21
Study 19935591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) therapy (1 hour/day for multiple sessions)
Number of subjects: 25
Study 19935591 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 25
Study 18626265 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d
Number of subjects: 599
Study 18626265 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/d
Number of subjects: 599
Study 18626265 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d
Number of subjects: 599
Study 18626265 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (all doses)
Number of subjects: 599
Study 16145844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralized solvent‐dehydrated cancellous bone allograft
Number of subjects: 7
Study 16145844 — intervention group
Group type: COMPARATOR
Intervention: Composite of DFDBA and deproteinized bovine bone xenograft (1:1)
Number of subjects: 7
Study 12697078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once a day
Number of subjects: 623
Study 12697078 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam, 3.375 g every 6 hours
Number of subjects: 623
Study 12697078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem for IAI
Number of subjects: 623
Study 12697078 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam for IAI
Number of subjects: 623
Study 12697078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem for SSSI
Number of subjects: 623
Study 12697078 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam for SSSI
Number of subjects: 623
Study 12697078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem for PI
Number of subjects: 623
Study 12697078 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam for PI
Number of subjects: 623
Study 12697078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 623
Study 10428144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 18
Study 10428144 — intervention group
Group type: COMPARATOR
Intervention: Control (without ketoconazole)
Number of subjects: 18
Study 7675994 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 0
Study 2075623 — intervention group
Group type: EXPERIMENTAL
Intervention: Billings ovulation method
Number of subjects: 850
Study 2075623 — intervention group
Group type: EXPERIMENTAL
Intervention: Local mucus method
Number of subjects: 850
Study 2075623 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorairaj modified mucus method
Number of subjects: 850
Study 6110912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (nasal prongs for at least 15 h daily, usually at 2 l/min)
Number of subjects: 87
Study 6110912 — intervention group
Group type: COMPARATOR
Intervention: No oxygen (controls)
Number of subjects: 87
Study 6110912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 87
Study 30449116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 90
Study 30449116 — intervention group
Group type: COMPARATOR
Intervention: Onset formula (control group 1)
Number of subjects: 90
Study 30449116 — intervention group
Group type: COMPARATOR
Intervention: Regular gluten consumption (control group 2)
Number of subjects: 90
Study 28433339 — intervention group
Group type: EXPERIMENTAL
Intervention: Snare cannulation
Number of subjects: 101
Study 28433339 — intervention group
Group type: COMPARATOR
Intervention: Retrograde cannulation
Number of subjects: 101
Study 25796338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HPV‐16/18 vaccine
Number of subjects: 7466
Study 25796338 — intervention group
Group type: COMPARATOR
Intervention: Control Hepatitis‐A vaccine
Number of subjects: 7466
Study 25796338 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control group (UCG)
Number of subjects: 7466
Study 22878782 — intervention group
Group type: EXPERIMENTAL
Intervention: PE in a spread added into a liquid meal
Number of subjects: 12
Study 22878782 — intervention group
Group type: EXPERIMENTAL
Intervention: PE given 30 min after a liquid meal as 100-g yoghurt drink
Number of subjects: 12
Study 22878782 — intervention group
Group type: COMPARATOR
Intervention: No PE added (control)
Number of subjects: 12
Study 21865332 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased supplemental zinc
Number of subjects: 67
Study 21865332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 67
Study 19490296 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet education programme
Number of subjects: 118
Study 19490296 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study 16460492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin and 6 MU interferon-alpha2b
Number of subjects: 76
Study 16460492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin and 10 MU interferon-alpha2b
Number of subjects: 76
Study 16460492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin and 6 MU interferon-alpha2b (group C)
Number of subjects: 76
Study 16460492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin and 10 MU interferon-alpha2b (group D)
Number of subjects: 76
Study 15297848 — intervention group
Group type: EXPERIMENTAL
Intervention: THAL-DEX (Thalidomide 100mg/day, Dexamethasone 40mg days 1-4 of each month)
Number of subjects: 120
Study 15297848 — intervention group
Group type: EXPERIMENTAL
Intervention: THAL-DEX
Number of subjects: 120
Study 15297848 — intervention group
Group type: COMPARATOR
Intervention: CC (Conventional Chemotherapy)
Number of subjects: 120
Study 11309010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1 mg/ml plus fentanyl 2 microg/ml administered via patient-controlled epidural analgesia (PCEA)
Number of subjects: 60
Study 11309010 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 1 mg/ml plus fentanyl 2 microg/ml administered via continuous epidural infusion (CEI)
Number of subjects: 60
Study 9389843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg kg‐1 in 0.9% saline (group T)
Number of subjects: 90
Study 9389843 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2 mg kg‐1 (group B)
Number of subjects: 90
Study 9389843 — intervention group
Group type: COMPARATOR
Intervention: Mixture of bupivacaine and tramadol (group BT)
Number of subjects: 90
Study 9389843 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 7702421 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 2000
Study 7702421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 3123153 — intervention group
Group type: EXPERIMENTAL
Intervention: latamoxef (4 g/day)
Number of subjects: 60
Study 3123153 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftriaxone (2 g/day)
Number of subjects: 60
Study 3123153 — intervention group
Group type: EXPERIMENTAL
Intervention: cefotaxime (4 g/day)
Number of subjects: 60
Study 28585263 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional sialendoscopy followed by intraductal steroid irrigations (group A)
Number of subjects: 22
Study 28585263 — intervention group
Group type: COMPARATOR
Intervention: Interventional sialendoscopy alone (group B)
Number of subjects: 22
Study 28031511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 15 mg/kg 15 minutes prior to surgery
Number of subjects: 60
Study 28031511 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 24158412 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic use according to local hospital guidelines
Number of subjects: 1252
Study 24158412 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravenous-oral switching
Number of subjects: 1252
Study 24158412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tertile of QI sum score
Number of subjects: 1252
Study 24158412 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tertile of QI sum score
Number of subjects: 1252
Study 23703835 — intervention group
Group type: EXPERIMENTAL
Intervention: HP3 (35% protein, 3 meals/day)
Number of subjects: 30
Study 23703835 — intervention group
Group type: EXPERIMENTAL
Intervention: HP6 (35% protein, 6 meals/day)
Number of subjects: 30
Study 23703835 — intervention group
Group type: COMPARATOR
Intervention: TD3 (traditional intake, 3 meals/day)
Number of subjects: 30
Study 21180082 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingkailing Injection (QKL) plus Ertong Qingfei oral liquid
Number of subjects: 206
Study 21180082 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin injection plus compound guaiacol potassium sulfonale oral solution
Number of subjects: 206
Study 19051852 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP10)
Number of subjects: 92
Study 19051852 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide (CP16)
Number of subjects: 92
Study 16084850 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily for 5 days
Number of subjects: 10
Study 16084850 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily for 5 days
Number of subjects: 10
Study 11880076 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy group
Number of subjects: 228
Study 11880076 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study 11880076 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (prostatectomy and control)
Number of subjects: 228
Study 11880076 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatectomy group
Number of subjects: 228
Study 10537956 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative treatment with gemcitabine in combination with best supportive care
Number of subjects: 184
Study 10537956 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 184
Study 7742905 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU of vitamin D3
Number of subjects: 53
Study 7742905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 2285657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg
Number of subjects: 10
Study 2285657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7301035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid (250 mg/day)
Number of subjects: 25
Study 7301035 — intervention group
Group type: COMPARATOR
Intervention: Chlorothiazide (500 mg/day)
Number of subjects: 25
Study 29654038 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) performed by trained nurses
Number of subjects: 750
Study 29654038 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) led by general practitioners (GPs)
Number of subjects: 750
Study 29654038 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 750
Study 27780251 — intervention group
Group type: EXPERIMENTAL
Intervention: PADOK intervention
Number of subjects: 1565
Study 27780251 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual school programme)
Number of subjects: 1565
Study 24742818 — intervention group
Group type: EXPERIMENTAL
Intervention: High blackcurrant juice drink (250ml, 4 times a day for 6 weeks)
Number of subjects: 66
Study 24742818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blackcurrant juice drink (250ml, 4 times a day for 6 weeks)
Number of subjects: 66
Study 24742818 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavored water, 250ml, 4 times a day for 6 weeks)
Number of subjects: 66
Study 22101900 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD; 200 IU/kg/d)
Number of subjects: 115
Study 22101900 — intervention group
Group type: COMPARATOR
Intervention: Low-dose (LD; 50 IU/kg 3 times/week)
Number of subjects: 115
Study 20421833 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg·kg of anhydrous caffeine
Number of subjects: 15
Study 20421833 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg·kg of anhydrous caffeine
Number of subjects: 15
Study 20421833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18291401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol for prevention of PPH
Number of subjects: 1620
Study 18291401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer than 4 prenatal visits
Number of subjects: 1620
Study 18291401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of iron supplementation
Number of subjects: 1620
Study 18291401 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal tear and birth weight (unknown until second stage of labor)
Number of subjects: 1620
Study 15746793 — intervention group
Group type: COMPARATOR
Intervention: Low-dose prednisone (control group)
Number of subjects: 60
Study 15746793 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (study group)
Number of subjects: 60
Study 15746793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (protocol biopsies)
Number of subjects: 60
Study 15746793 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal group (1 year follow-up)
Number of subjects: 60
Study 14567157 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat with a hypocaloric diet
Number of subjects: 0
Study 14567157 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 10893015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 15
Study 10893015 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 15
Study 10893015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10893015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine vs Loratadine
Number of subjects: 15
Study 8630596 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled budesonide (1,600 micrograms/d)
Number of subjects: 85
Study 8630596 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inhaled budesonide (400 micrograms/d)
Number of subjects: 85
Study 8630596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline (600 mg/d)
Number of subjects: 85
Study 8630596 — intervention group
Group type: COMPARATOR
Intervention: Control group (smokers)
Number of subjects: 85
Study 8630596 — intervention group
Group type: COMPARATOR
Intervention: All three groups (including smokers)
Number of subjects: 85
Study 1564656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral carbachol (0.01%)
Number of subjects: 162
Study 1564656 — intervention group
Group type: COMPARATOR
Intervention: ECCE without carbachol
Number of subjects: 162
Study 1564656 — intervention group
Group type: COMPARATOR
Intervention: ECCE with IOL implantation without carbachol
Number of subjects: 162
Study 1564656 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE with or without IOL implantation
Number of subjects: 162
Study 2857611 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (RX 781094), an alpha 2-antagonist, administered at low intra-arterial doses
Number of subjects: 0
Study 2857611 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (RX 781094), an alpha 2-antagonist, administered at higher doses
Number of subjects: 0
Study 2857611 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounds with mixed alpha 2- and alpha 1-antagonist properties
Number of subjects: 0
Study 2857611 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan on arterial segments in vitro
Number of subjects: 0
Study 31355677 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 0
Study 31355677 — intervention group
Group type: COMPARATOR
Intervention: FVIII prophylaxis
Number of subjects: 0
Study 29582212 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (1.7, 3.4, or 6.8 g)
Number of subjects: 44
Study 29582212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29582212 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112
Number of subjects: 44
Study 27097165 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 2 mg
Number of subjects: 106
Study 27097165 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 20 mg
Number of subjects: 106
Study 27097165 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Number of subjects: 106
Study 27097165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 25953301 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 29
Study 25953301 — intervention group
Group type: COMPARATOR
Intervention: Untreated OSA
Number of subjects: 29
Study 25953301 — intervention group
Group type: COMPARATOR
Intervention: Controls without OSA
Number of subjects: 29
Study 22710579 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (Gp‐L, 30 ml three times per day)
Number of subjects: 235
Study 22710579 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Gp‐P, three capsules per day containing 112.5 billion viable lyophilized bacteria per capsule)
Number of subjects: 235
Study 22710579 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Gp‐N)
Number of subjects: 235
Study 22710579 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (Gp‐L) vs Probiotics (Gp‐P)
Number of subjects: 235
Study 22710579 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Gp‐L, Gp‐P, Gp‐N)
Number of subjects: 235
Study 22710579 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric tests
Number of subjects: 235
Study 20406223 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 0
Study 20406223 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 1000 mg
Number of subjects: 0
Study 20406223 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 1500 mg
Number of subjects: 0